Respiratory

Candidate
Targets
Partner
Our Commercial Rights
Discovery
Preclinical
Phase 1
Phase 2
Candidate PRS-220
Targets

CTGF

Partner

n/a

Commercial Rights

Worldwide

Discovery complete
Preclinical complete
Phase 1 in progress
Phase 2 not started
Candidate PRS-400
Targets

Jagged-1

Partner

n/a

Commercial Rights

Worldwide

Discovery complete
Preclinical in progress
Phase 1 not started
Phase 2 not started

Immuno-Oncology

Candidate
Targets
Partner
Our Commercial Rights
Discovery
Preclinical
Phase 1
Phase 2
Candidate PRS-344/S095012
Targets

4-1BB/PD-L1

Partner

Servier

Commercial Rights

Royalties

Discovery complete
Preclinical complete
Phase 1 in progress
Phase 2 not started
Candidate PRS-346/SGN-BB228
Targets

4-1BB/CD228

Partner

Commercial Rights

Royalties

Discovery complete
Preclinical complete
Phase 1 in progress
Phase 2 not started
Candidate PRS-342/BOS-342
Targets

4-1BB/GPC3

Partner

Commercial Rights

Royalties

Discovery complete
Preclinical complete
Phase 1 in progress
Phase 2 not started
Candidate Candidate Seagen Programs‡
Targets

n.d.

Partner

Commercial Rights

US Co-Promotion Option

Discovery in progress
Preclinical not started
Phase 1 not started
Phase 2 not started

‡ 2 active bispecific programs in collaboration with Seagen in addition to PRS-346/SGN-BB228 listed above.

Programs that Stand up to Scrutiny

Our Scientific Advisory Board holds us to the highest standards of scientific practice.

View Advisory Board